8-K: Boston Scientific Appoints David Habiger to Board of Directors, Expanding Board to Eleven Members

Boston Scientific has appointed David Habiger to its board of directors, increasing the board size to eleven members, effective July 30, 2024.

Summary

• Boston Scientific has increased its board of directors from ten to eleven members.
• David Habiger was appointed as a new director, effective July 30, 2024.
• Mr. Habiger will serve on the Audit Committee and the Executive Compensation and Human Resources Committee.
• He will receive a prorated cash retainer of approximately $94,175 and an equity award valued at approximately $161,981.
• The actual number of shares will be determined on August 1, 2024.
• Boston Scientific will enter into an indemnification agreement with Mr. Habiger.
• Mr. Habiger has over 30 years of business leadership experience and is currently the CEO of J.D. Power.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of an experienced director and the company's forward-looking statements. There are no negative aspects mentioned.

Positives

• The appointment of David Habiger brings significant business leadership experience to the board.
• Mr. Habiger's background in technology companies could provide valuable insights for Boston Scientific.
• The expansion of the board may bring diverse perspectives and expertise.

Future Outlook

Boston Scientific expects Mr. Habiger's insights to contribute to the company's continued growth and delivery of solutions.

Management Comments

• Mike Mahoney, chief executive and chairman of the board, stated, 'We are pleased to expand our board of directors with an accomplished executive who brings a wealth of experience leading technology companies through times of pivotal growth.'
• Mike Mahoney also said, 'We welcome Dave and look forward to his insights as Boston Scientific continues to deliver solutions that transform lives.'

Industry Context

The appointment of a seasoned technology executive like David Habiger reflects a trend in the medical technology industry to incorporate expertise from other sectors to drive innovation and growth.

Comparison to Industry Standards

• Many large medical device companies have boards with a mix of industry experts, financial professionals, and leaders from other sectors.
• The compensation package for Mr. Habiger is consistent with standard non-employee director compensation programs at similar companies.
• Companies like Medtronic and Abbott also have diverse boards with members from various backgrounds.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced director positively.
• Employees may see this as a sign of the company's commitment to growth and innovation.

Next Steps

• The actual number of shares to be granted to Mr. Habiger will be determined on August 1, 2024.
• Boston Scientific will enter into an indemnification agreement with Mr. Habiger.

Key Dates

Keywords

Board of Directors, David Habiger, Corporate Governance, Director Appointment, Executive Compensation, Boston Scientific, Medical Technology